Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Last Hour:
Last 24 Hours:

Glomerulonephritis Treatment Pipeline Review H2 2016

Friday, October 14, 2016 1:36
% of readers think this story is Fact. Add your two cents.

(Before It's News)


‘Glomerulonephritis – Pipeline Review, H2 2016’, provides an overview of the Glomerulonephritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Glomerulonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Glomerulonephritis and features dormant and discontinued projects.

Request a sample report @

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.


- The report provides a snapshot of the global therapeutic landscape of Glomerulonephritis 
- The report reviews pipeline therapeutics for Glomerulonephritis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Glomerulonephritis therapeutics and enlists all their major and minor projects 
- The report assesses Glomerulonephritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Glomerulonephritis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Glomerulonephritis 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Glomerulonephritis pipeline depth and focus of Indication therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @



Key points in table of content

Table of Contents 2 
List of Tables 6 
List of Figures 7 
Introduction 8 
Global Markets Direct Report Coverage 8 
Glomerulonephritis Overview 9 
Therapeutics Development 10 
Pipeline Products for Glomerulonephritis – Overview 10 
Pipeline Products for Glomerulonephritis – Comparative Analysis 11 
Glomerulonephritis – Therapeutics under Development by Companies 12 
Glomerulonephritis – Therapeutics under Investigation by Universities/Institutes 15 
Glomerulonephritis – Pipeline Products Glance 16 
Late Stage Products 16 
Clinical Stage Products 17 
Early Stage Products 18 
Glomerulonephritis – Products under Development by Companies 19 
Glomerulonephritis – Products under Investigation by Universities/Institutes 21 
Glomerulonephritis – Companies Involved in Therapeutics Development 22 
Achillion Pharmaceuticals, Inc. 22 
Alexion Pharmaceuticals Inc 23 
Amyndas Pharmaceuticals LLC 24 
Anthera Pharmaceuticals Inc 25 
Avexxin AS 26 
Biogen Inc 27 
Complexa, Inc. 28 
Dimerix Bioscience Pty Ltd 29 
GlaxoSmithKline Plc 30 
Mallinckrodt Plc 31 
Omeros Corporation 32 
Pfizer Inc. 33 
Pharmalink AB 34 
Retrophin Inc. 35 
Rigel Pharmaceuticals, Inc. 36 
Shire Plc 37 
Toray Industries, Inc. 38 
Variant Pharmaceuticals, Inc. 39 
Glomerulonephritis – Therapeutics Assessment 40 
Assessment by Monotherapy Products 40 
Assessment by Combination Products 41 
Assessment by Target 42 
Assessment by Mechanism of Action 44 
Assessment by Route of Administration 46 
Assessment by Molecule Type 48 
Drug Profiles 50 
(irbesartan + propagermanium) – Drug Profile 50 
Product Description 50 
Mechanism Of Action 50 
R&D Progress 50 
ACH-4471 – Drug Profile 52 
Product Description 52 
Mechanism Of Action 52 
R&D Progress 52 
AMY-101 – Drug Profile 54 
Product Description 54 
Mechanism Of Action 54 
R&D Progress 54 
AVX-002 – Drug Profile 56 
Product Description 56 
Mechanism Of Action 56 
R&D Progress 56 
belimumab – Drug Profile 57 
Product Description 57 
Mechanism Of Action 57 
R&D Progress 57 
blisibimod – Drug Profile 63 
Product Description 63 
Mechanism Of Action 63 
R&D Progress 63 
budesonide – Drug Profile 69 
Product Description 69 
Mechanism Of Action 69 
R&D Progress 69 
corticotropin – Drug Profile 71 
Product Description 71 
Mechanism Of Action 71 
R&D Progress 71 
CXA-10 – Drug Profile 73 
Product Description 73 
Mechanism Of Action 73 
R&D Progress 73 
eculizumab – Drug Profile 75 
Product Description 75 
Mechanism Of Action 75 
R&D Progress 75 
fostamatinib disodium – Drug Profile 84 
Product Description 84 
Mechanism Of Action 84 
R&D Progress 84 
losmapimod – Drug Profile 89 
Product Description 89 
Mechanism Of Action 89 
R&D Progress 89 
Monoclonal Antibodies to Inhibit Glycoprotein Ib Alpha for Vasculitis and Glomerulonephritis – Drug Profile 91 
Product Description 91 
Mechanism Of Action 91 
R&D Progress 91 
OMS-721 – Drug Profile 92 
Product Description 92 
Mechanism Of Action 92 
R&D Progress 92 
PF-1355 – Drug Profile 97 
Product Description 97 
Mechanism Of Action 97 
R&D Progress 97 
Recombinant Enzyme for Immunoglobulin A Nephropathy – Drug Profile 98 
Product Description 98 
Mechanism Of Action 98 
R&D Progress 98 
rituximab – Drug Profile 99 
Product Description 99 
Mechanism Of Action 99 
R&D Progress 99 
SHP-627 – Drug Profile 103 
Product Description 103 
Mechanism Of Action 103 
R&D Progress 103 
Small Molecule to Inhibit Vitamin K Epoxide Reductase for Glomerulonephritis – Drug Profile 105 
Product Description 105 
Mechanism Of Action 105 
R&D Progress 105 
sparsentan – Drug Profile 106 
Product Description 106 
Mechanism Of Action 106 
R&D Progress 106 
TM-5484 – Drug Profile 108 
Product Description 108 
Mechanism Of Action 108 
R&D Progress 108 
Vaccine to Target CD40 for Membranous Glomerulonephritis – Drug Profile 109 
Product Description 109 
Mechanism Of Action 109 
R&D Progress 109 
VAR-200 – Drug Profile 110 
Product Description 110 
Mechanism Of Action 110 
R&D Progress 110 
Glomerulonephritis – Dormant Projects 111 
Glomerulonephritis – Discontinued Products 113 
Glomerulonephritis – Product Development Milestones 114 
Featured News & Press Releases 114 
Aug 01, 2016: Dimerix announces outcomes of DMX-200 pre-IND meeting with the FDA 114 
May 17, 2016: First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar Gel for Rare Cause of Nephrotic Syndrome 115 
Mar 30, 2016: Retrophin Completes Enrollment of Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis 115 
Mar 04, 2016: Amyndas’ lead candidate AMY-101 receives orphan drug status from the FDA and the EMA for the treatment of C3 glomerulopathy 116 
Dec 14, 2015: Dimerix receives Orphan Designation for its lead drug candidate targeting patients with chronic kidney disease 116 
Nov 16, 2015: Retrophin Receives European Orphan Drug Designation for Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis 117 
Jan 09, 2015: Ligand Partner Retrophin Receives Orphan Drug Designation for Sparsentan 117 
Feb 25, 2013: Ligand Receives $1.4m Milestone Payment From Retrophin 118 
Jan 09, 2013: Ligand Receives Equity Milestone Payment From Retrophin 118 
Oct 31, 2012: Pharmalink Signs Manufacturing Agreement For Nefecon 119 
Oct 13, 2010: Pharmalink Receives US Orphan Drug Designation For Nefecon 120 
Oct 26, 2009: Japanese Patent granted for Pharmalink AB’s Nefecon 120 
Apr 29, 2009: Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon 121 
Mar 31, 2008: Pharmalink Reports Promising Interim Results From Phase II Trials For New Renal Disease Drug Nefecon 121 
Appendix 123 
Methodology 123 
Coverage 123 
Secondary Research 123 
Primary Research 123 
Expert Panel Validation 123 
Contact Us 123 
Disclaimer 124

Get this report @


Contact US:


Partner Relations & Marketing Manager

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)           

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.